Phase II trial of motexafin gadolinium [Xcytrin; Pharmacyclics] with whole brain radiation therapy followed by stereotactic radiosurgery boost in the treatment of patients with brain metastases
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Motexafin gadolinium (Primary)
- Indications Brain metastases; Cancer metastases
- Focus Adverse reactions
- Sponsors Pharmacyclics
- 18 Mar 2014 Primary end points added as reported by ClinicalTrials.gov
- 18 Dec 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 13 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.